Detail of "366789-02-8"

CAS Number:
366789-02-8
Name:
2-Thiophenecarboxamide,5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-
Superlist Name:
Rivaroxaban
Molecular Structure:
Formula:
C₁₉H₁₈ClN₃O₅S
Molecular Weight:
435.88
Synonyms:
5-Chloro-N-[[(S)-3-(4-(3-oxomorpholin-4-yl)phenyl)-2-oxo-1,3-oxazolidin-5-yl]methyl]-thiophene-2-carboxamide;BAY 59-7939;Xarelto;
Density:
1.46 g/cm³
Boiling Point:
732.609 °C at 760 mmHg
Flash Point:
396.868 °C

Famous Chemical Enterprises

Livzon
Total
Shell
Dupont
Exxonmobil
Akzonobel
Basf
Bayer
BP

Other Products

Page：1/2

Supplier Location
Supplier Location
- China (Mainland)(42)
- United States(2)
- Cameroon(1)
- Germany(1)
- India(1)
Business Type
Business Type
- Lab/Research institutions(9)
- Manufacturers(1)
- Other(1)
- Trading Company(33)
Certificates
Certificates
- ISO(1)
- Production License(1)

Please post your buying leads>>

Display：

Manufacturer
Enterprise Authentication
Suppiers of more reward points first
New supplier

Total:47 Page 1 of 2 1 2 Next>>

Please post your buying leads,so that our qualified suppliers will soon contact you!
*Required Fields

Reference

Rivaroxaban: factor Xa inhibitor anticoagulant: All Rights Reserved. Rivaroxaban: factor Xa inhibitor anticoagulant. Escolar, G.; Villalta, J.; Casals, F.; Bozzo, J.; Serradell, N.; Bolos, J. ( Servicio de Hemoterapia y Hemostasia, Unidad de Trombosis, Centre de Diagnostic Biomedic, Hospital Clinic, Universidad de Barcelona, Spain). Drugs of the Future, 31(6), 484-493 (English) 2006 Prous Science. CODEN: DRFUD4. ISSN: 0377-8282. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 27 A review. Regulation of excessive coagulation through inhibition of activated serine proteases has proven to be a successful strategy for the prevention of thrombotic complications. Unfractionated heparin (UH) and low-mol.-wt. heparins (LMWHs) bind to antithrombin III (ATIII) and accelerate the ability of this enzyme to inhibit activated serine proteases, thus reducing the overall activation of the coagulation cascade.Several substances with their cas registry numbers 9002-05-5 and 366789-02-8 may be metioned in this study. Rivaroxaban (Bay-59-7939) is an oral, direct factor Xa (FXa) inhibitor developed by Bayer which belongs to a new class of small-mol., active site-directed FXa inhibitors. Rivaroxaban does not require plasma cofactors to exert its regulatory effect on coagulation and it does not interfere with other serine proteases. Rivaroxaban demonstrated excellent in vivo antithrombotic activity in preliminary studies in animal models, with maximal inhibition of FX activity approx. 3 h after oral dosing. In pharmacokinetic studies, the drug was rapidly absorbed and eliminated. In vitro and clin. studies suggested that drug-drug interactions are unlikely. Two major studies have evaluated the efficacy and safety of rivaroxaban in the prophylaxis of thrombosis in patients undergoing orthopedic surgery. In these studies, rivaroxaban (2.5-10 mg b.i.d.) compared favorably with enoxaparin (40 mg once daily). .

Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopedic surgery: All Rights Reserved. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopedic surgery. Eriksson, Bengt I.; Quinlan, Daniel J. (Department of Orthopaedics Surgery, Sahlgrenska University Hospital/Oestra, Goeteborg, Swed.). Drugs, 66(11), 1411-1429 (English) 2006 Adis International Ltd. CODEN: DRUGAY. ISSN: 0012-6667. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) A review. Current anticoagulant provision is dominated by parenteral heparin and oral warfarin, which act by inhibiting several steps of the coagulation pathway indirectly. Recent research efforts have focused on the identification of small mol. inhibitors of the coagulation enzymes as novel therapies for thrombotic disorders. There has been particular success in developing nonpeptidic, orally available, small mols. to directly inhibit the key proteases, factor IIa and factor Xa.Several substances with their cas registry numbers 366789-02-8 and 211915-06-9 may be metioned in this study. Of the new oral anticoagulants in development, the two agents in the most advanced stage are dabigatran etexilate (BIBR 1048) and rivaroxaban (BAY 59-7939), which inhibit factor IIa and factor Xa, resp. Other agents in the early stages of development include several Xa inhibitors (LY-517717, YM150, DU-176b and apixaban [BMS-562247]), a factor IXa inhibitor (TTP889), and an orally active glycosaminoglycan enhancer (odiparcil [SB-424323]), which indirectly enhances thrombin inhibition via heparin cofactor II. Results have been reported from important, phase II dose-finding studies, and a no. of registration-track phase III studies have been initiated, reflecting the drive towards potentially more effective, but primarily safer and more convenient therapies for the prevention and treatment of venous and arterial thrombosis. Indeed, two unmet needs for anticoagulation that can be easily identified are safety and ease of use. Safety relates primarily to the incidence of major bleeding and this remains the key concern of orthopedic surgeons, over and above any efficacy advantage, and convenience of use, which centers on oral administration replacing the need for injections. The clin. development of these new anticoagulants is following the well tested strategy of dose-ranging and registration studies in major orthopedic surgery, prior to development in arterial indications. There are a no. of subtle issues, including the timing of the first perioperative dose, duration of prophylactic treatment and definition/assessment of study endpoints that can influence study outcome and require careful consideration when evaluating study results with new agents and in the comparison with established agents, and which are considered in this review. It is anticipated that over the next 3 years, at least one of these agents will be successfully licensed for the prevention of venous thromboembolism after major orthopedic surgery, which will act as a springboard for the gradual replacement of current anticoagulants. .

Detail of "366789-02-8"

2-Thiophenecarboxamide,5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-

Famous Chemical Enterprises

Related products

Other Products

Supplier Location

Business Type

Certificates

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

CAS No.366789-02-8 Rivaroxaban

Reference